30 September 2021
Veeda Clinical Research Ltd on Wednesday draft papers for a ₹831.6 crore initial public offering (IPO) that will see private equity firm CX Partners make a partial exit.
The IPO consists of a fresh issue of ₹331.60 crore and an offer for sale (OFS) of ₹500 crore by shareholders and promoters.
The OFS comprises a ₹8.08 crore sale by CX Alternative Investment Fund, ₹90.19 crore sale by Arabelle Financial Services Ltd, ₹259.77 crore sale by Bondway Investments Inc., ₹4 lakh sale by Stevey International Corporation, and a ₹141.93 crore sale by Basil Pvt. Ltd.
CX Alternative Investment Fund, Bondway, Basil, and Arabelle are all CX Partners entities. CX Alternative Investment Fund holds 2.98% stake, Arabelle 4.51% stake, Bondway 28.36% stake, Stevey 0.002% stake, and Basil 52.42% stake.

Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Pre Ipo
Upcoming IPO
Unicorn
Mutual Fund License No.:
IRDA Code (1):
IRDA Code (2):
Startup India Certificate No.:
Other Websites
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India